Data extracted from existing publicly- and privately-conducted clinical trials to address amyotrophic lateral sclerosis (ALS)

The largest collection of data from clinical trials in amyotrophic lateral sclerosis (ALS), representing more than 8,500 individuals, is now live.

The Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database merges data from existing publicly- and privately-conducted ALS clinical trials to generate an invaluable resource for accelerating discovery in the field of ALS.  Understanding the progression of ALS better can help researchers streamline clinical trials, reducing subject numbers and costs.  

The database contains data from the organizers of 18 Phase 2 or 3 trials for ALS. Contributors include Sanofi of Paris, France; Regeneron, headquartered in Tarrytown, New York; Teva Pharmaceuticals in Petah Tikva, Israel; and Novartis, based in Basel, Switzerland.

Most of the longitudinal data, from both placebo and treatment participants, spans about one year, with no identifying information to protect the anonymity of the participants and proprietary interests. The database includes several elements such as medical history and lab results. Over time, the organizers plan to add other features, for example, adverse events and the approximate date of the trial.

More information available on the PRO-ACT website link below:

Files

Links

https://nctu.partners.org/ProACT/Home/About

January 11, 2013